Mubritinib
| Code | Size | Price |
|---|
| AG-CR1-3755-M005 | 5 mg | £40.00 |
Quantity:
| AG-CR1-3755-M025 | 25 mg | £130.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short Term: +4°C Long Term: -20°C
Documents
Further Information
Alternate Names/Synonyms:
TAK-165; TAK 165; CID 6444692
Appearance:
White to off-white solid.
CAS:
366017-09-6
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.
InChi:
InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
InChiKey:
ZTFBIUXIQYRUNT-MDWZMJQESA-N
Long Description:
Chemical. CAS: 366017-09-6. Formula: C25H23F3N4O2. MW: 468.5. Mubritinib (TAK-165) is a selective inhibitor of the human epidermal growth factor receptor 2 (EGFR2; HER2), inhibiting HER2 phosphorylation with an IC50 value of 6nM. It is 4000-fold selective over EGFR, FGFR, PDGFR, JAK1, Src and Blk (IC50 > 25µM). Mubritinib inhibits the proliferation of breast, bladder, kidney and prostate cancer cells in vitro and in vivo. Mubritinib was shown to inhibit autophagy in a HER2-independent manner in cancer cells. Recently shown to be a mitochondrial electron transport chain complex I (NADH-CoQ reductase) inhibitor. Mubritinib functions through ubiquinone-dependent inhibition of electron transport chain (ETC) complex I activity and consequently oxidative phosphorylation (OXPHOS). This agent could be useful for immunometabolism research. Inhibition of electron transport chain in mitochondria leads to blocking of the transfer of electrons from iron-sulfur centers in complex I to ubiquinone. By inhibiting the mitochondrial respiratory complex I, this agent reduces cardiac-cell beat rate, with prolonged exposure resulting in cell death. Complex I inhibition is directly linked to anti-cancer cell activity.
MDL:
MFCD09954135
Molecular Formula:
C25H23F3N4O2
Molecular Weight:
468.5
Package Type:
Plastic Vial
Product Description:
Mubritinib (TAK-165) is a selective inhibitor of the human epidermal growth factor receptor 2 (EGFR2; HER2), inhibiting HER2 phosphorylation with an IC50 value of 6nM. It is 4000-fold selective over EGFR, FGFR, PDGFR, JAK1, Src and Blk (IC50 > 25µM). Mubritinib inhibits the proliferation of breast, bladder, kidney and prostate cancer cells in vitro and in vivo. Mubritinib was shown to inhibit autophagy in a HER2-independent manner in cancer cells. Recently Mubritinib has been shown to be a mitochondrial electron transport chain complex I (NADH-CoQ reductase) inhibitor. Mubritinib functions through ubiquinone-dependent inhibition of electron transport chain (ETC) complex I activity and consequently oxidative phosphorylation (OXPHOS). This agent could be useful for immunometabolism research. Inhibition of electron transport chain in mitochondria leads to blocking of the transfer of electrons from iron-sulfur centers in complex I to ubiquinone. By inhibiting the mitochondrial respiratory complex I, this agent reduces cardiac-cell beat rate, with prolonged exposure resulting in cell death. Complex I inhibition is directly linked to anti-cancer cell activity.
Purity:
>95%
SMILES:
FC(F)(F)C(C=C1)=CC=C1/C=C/C2=NC(COC3=CC=C(CCCCN4N=NC=C4)C=C3)=CO2
Solubility Chemicals:
Soluble in DMSO (5mg/ml) or ethanol (1mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer: S.S. Sridhar, et al.; Lancet Oncol. 4, 397 (2003) (Review) | Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo: J. Nagasawa, et al.; Int. J. Urol. 13, 587 (2006) | Small molecule HER-2 tyrosine kinase inhibitors: N. Spector, et al.; Breast Cancer Res. 9, 205 (2007) | Mubritinib is used in selective targeting of CTNNB1-, KRAS-or MYC-driven human cancer cell growth by combinations of existing drugs: J.C. Uitdehaag, et al.; PLoS One 10, 0125021 (2015) | Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death: A.T. Ouchida, et al.; Cell Death Dis. 9, 138 (2018) | Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia: I. Baccelli, et al.; Cancer Cell 36, 84 (2019) | Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism: A. Calderon, et al.; Oncotarget 11, 4224 (2020) | Identification of a novel toxicophore in anti-cancer chemotherapeutics that targets mitochondrial respiratory complex I: Z.A. Stephenson, et al.; Elife 9, e55845 (2020)